Dr. Saad on the Safety Profile of Apalutamide in M0CRPC

Published June 24, 2020

Views 245 | Likes 0 | Comments 0

Views#2,272,323

Views#393,734

Channel

OncLive

26.8K subs•17.3K videos•Mar 2011

Views

245

Likes

0

Comments

0

Performance vs. channel

Outlier score

Engagement rate

Revenue estimate

Total (all-time): $0 – $0

Based on estimated $0.7–$2 CPM.

More features coming

We're working on new analytics and tools. Stay tuned.

About

Fred Saad, MD, FRCS, discusses the safety profile of apalutamide in nonmetastatic castration-resistant prostate cancer. Website: https://www.onclive.com Twitter: https://twitter.com/OncLive Facebook: https://www.facebook.com/OncLive/ LinkedIn: https://www.linkedin.com/company/onclive

Published: June 24, 2020
Made for kids: No

More features coming

We're working on new analytics and tools. Stay tuned.